Comparable stake leader
ACORN BIOVENTURES, L.P.
SEC ownership of PUMA BIOTECHNOLOGY, INC.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001401667.
Disclosed value leader
ACORN CAPITAL ADVISORS, LLC
Comparable rows
50/50
Latest evidence
30 Jun 2026
- Public ticker
- PBYI on Nasdaq
- Parsed ownership sources
-
13D/G, 13F, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
ACORN BIOVENTURES, L.P.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
ACORN BIOVENTURES, L.P.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001401667
- Issuer location
- Los Angeles, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of PUMA BIOTECHNOLOGY, INC. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ACORN BIOVENTURES, L.P.
Disclosed value leader
ACORN CAPITAL ADVISORS, LLC
Comparable rows
50/50
Latest evidence
30 Jun 2026
13D/G
13F
3/4/5
Lead comparable stake: 8%
13D/G row: ACORN BIOVENTURES, L.P.
Showing 1-8 of 50 holder rows.
Quick read
ACORN BIOVENTURES, L.P. leads the comparable SEC ownership view at 8%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ACORN BIOVENTURES, L.P.'s linked filing trail.
Comparable ownership
Top 5
ACORN BIOVENTURES, L.P.
8%
BlackRock, Inc.
5.6%
MILLENNIUM MANAGEMENT LLC
3.9%
Brian M. Stuglik
0.23%
Allison Dorval
0.18%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ACORN BIOVENTURES, L.P. |
13D/G
Anders Hove
|
8%
|
$11,859,557
3,940,052 shares
|
+$1,988,442 | 31 Dec 2024 |
| BlackRock, Inc. |
13F
13D/G
Company
|
5.6%
from 13D/G
|
$30,856,410
3,804,736 shares
|
— | 30 Jun 2026 |
| MILLENNIUM MANAGEMENT LLC |
13D/G
13F
Company
|
3.9%
|
$5,701,319
1,894,126 shares
|
$0 | 31 Dec 2024 |
| Brian M. Stuglik |
3/4/5
Director
|
0.23%
|
$819,652
113,858 shares
|
-$58,311 | 11 Jun 2026 |
| Allison Dorval |
3/4/5
Director
|
0.18%
|
$653,516
90,780 shares
|
-$83,579 | 11 Jun 2026 |
| Michael Patrick Miller |
3/4/5
Director
|
0.16%
|
$517,590
81,000 shares
|
-$97,228 | 11 Jun 2026 |
| Alessandra Cesano |
3/4/5
Director
|
0.14%
|
$439,951
68,850 shares
|
— | 11 Jun 2026 |
| Troy E. Wilson |
3/4/5
Director
|
0.12%
|
$433,648
60,300 shares
|
-$77,748 | 11 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$1,503,247.
Buys
$0
Insiders: 0
Sells
$1,503,247
Insiders: 9
Net
-$1,503,247
Shares: -216,296
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 216,296
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 141,414 | $0 | $1,084,258 | -$1,084,258 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 54,882 | $0 | $321,760 | -$321,760 |
| 9-12 | 0 | 20,000 | $0 | $97,228 | -$97,228 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-13 of 13 reporting-owner rows connected to PUMA BIOTECHNOLOGY, INC.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
13
Largest Forms 3/4/5 holder
Alan H. Auerbach
Net 12M change
-$1,503,245
Latest report
06 Jul 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Alan H. Auerbach | President and CEO, Director, 10%+ Owner | $60,003,187 | -$568,929 | -0.94% | Filing P/S | 06 Jul 2026 |
| Maximo F. Nougues | Chief Financial Officer | $1,905,753 | -$141,743 | -6.9% | Filing P/S | 06 Jul 2026 |
| Douglas M. Hunt | The Reporting Person is the Senior Vice President of Regulatory Affairs of the Issuer. | $1,626,497 | -$122,600 | -7% | Filing P/S | 06 Jul 2026 |
| Brian M. Stuglik | Director | $819,652 | -$58,311 | -6.6% | Filing P/S | 11 Jun 2026 |
| Allison Dorval | Director | $653,516 | -$83,579 | -11% | Filing P/S | 11 Jun 2026 |
| Alvin F. Wong | Chief Scientific Officer | $633,593 | Mixed | 12 Feb 2024 | ||
| Michael Patrick Miller | Director | $517,590 | -$97,228 | -16% | Mixed | 11 Jun 2026 |
| Jeffrey Jerome Ludwig | Chief Commercial Officer | $494,161 | Mixed | 07 Feb 2025 | ||
| Alessandra Cesano | Director | $439,951 | Mixed | 11 Jun 2026 | ||
| Troy E. Wilson | Director | $433,648 | -$77,748 | -15% | Mixed | 11 Jun 2026 |
| Jay M. Moyes | Director | $420,968 | -$158,796 | -27% | Filing P/S | 11 Jun 2026 |
| Adrian Senderowicz | Director | $194,310 | -$194,311 | -50% | Filing P/S | 11 Jun 2026 |
| Ann C. Miller | Director | $182,720 | Mixed | 15 Jun 2021 |
Recent insider transactions for PUMA BIOTECHNOLOGY, INC.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Alan H. Auerbach | PBYI | Common Stock | Sale | -0.6% | $364,051 | $8.26 | -44,058 | 7,261,671 | 06 Jul 2026 | Direct |
| Douglas M. Hunt | PBYI | Common Stock | Sale | -4.12% | $69,905 | $8.26 | -8,460 | 196,841 | 06 Jul 2026 | Direct |
| Maximo F. Nougues | PBYI | Common Stock | Sale | -3.91% | $77,557 | $8.26 | -9,386 | 230,637 | 06 Jul 2026 | Direct |
| Troy E. Wilson | PBYI | Common Stock | Sale | -15.3% | $77,748 | $7.20 | -10,800 | 59,750 | 12 Jun 2026 | Direct |
| Brian M. Stuglik | PBYI | Common Stock | Sale | -6.64% | $58,311 | $7.20 | -8,100 | 113,858 | 12 Jun 2026 | Direct |
| Adrian Senderowicz | PBYI | Common Stock | Sale | -50% | $194,311 | $7.20 | -27,000 | 27,000 | 12 Jun 2026 | Direct |
| Jay M. Moyes | PBYI | Common Stock | Sale | -27.4% | $158,796 | $7.22 | -22,000 | 58,322 | 12 Jun 2026 | Direct |
| Allison Dorval | PBYI | Common Stock | Sale | -11.3% | $83,579 | $7.20 | -11,610 | 90,780 | 12 Jun 2026 | Direct |
| Troy E. Wilson | PBYI | Common Stock | Award | 62% | 27,000 | 70,550 | 11 Jun 2026 | Direct | ||
| Brian M. Stuglik | PBYI | Common Stock | Award | 28.4% | 27,000 | 121,958 | 11 Jun 2026 | Direct | ||
| Adrian Senderowicz | PBYI | Common Stock | Award | 100% | 27,000 | 54,000 | 11 Jun 2026 | Direct | ||
| Michael Patrick Miller | PBYI | Common Stock | Award | 50% | 27,000 | 81,000 | 11 Jun 2026 | Direct | ||
| Jay M. Moyes | PBYI | Common Stock | Award | 50.6% | 27,000 | 80,322 | 11 Jun 2026 | Direct | ||
| Allison Dorval | PBYI | Common Stock | Award | 35.8% | 27,000 | 102,390 | 11 Jun 2026 | Direct | ||
| Alessandra Cesano | PBYI | Common Stock | Award | 64.5% | 27,000 | 68,850 | 11 Jun 2026 | Direct | ||
| Alan H. Auerbach | PBYI | Common Stock | Award | 2.24% | 159,778 | 7,305,729 | 18 Feb 2026 | Direct | ||
| Alan H. Auerbach | PBYI | Stock Option (Right to Buy) | Award | 227,474 | 227,474 | 18 Feb 2026 | Direct | |||
| Douglas M. Hunt | PBYI | Common Stock | Award | 31.7% | 49,394 | 205,301 | 18 Feb 2026 | Direct | ||
| Douglas M. Hunt | PBYI | Stock Option (Right to Buy) | Award | 70,321 | 70,321 | 18 Feb 2026 | Direct | |||
| Maximo F. Nougues | PBYI | Common Stock | Award | 24.2% | 46,739 | 240,023 | 18 Feb 2026 | Direct | ||
| Maximo F. Nougues | PBYI | Stock Option (Right to Buy) | Award | 66,541 | 66,541 | 18 Feb 2026 | Direct | |||
| Alan H. Auerbach | PBYI | Common Stock | Sale | -0.25% | $105,893 | $5.88 | -18,012 | 7,145,951 | 07 Jan 2026 | Direct |
| Douglas M. Hunt | PBYI | Common Stock | Sale | -3.12% | $29,477 | $5.88 | -5,014 | 155,907 | 07 Jan 2026 | Direct |
| Maximo F. Nougues | PBYI | Common Stock | Sale | -3.21% | $37,655 | $5.88 | -6,405 | 193,284 | 07 Jan 2026 | Direct |
| Alan H. Auerbach | PBYI | Common Stock | Sale | -0.24% | $98,986 | $5.84 | -16,938 | 7,163,963 | 06 Jan 2026 | Direct |
| Douglas M. Hunt | PBYI | Common Stock | Sale | -2.41% | $23,218 | $5.84 | -3,973 | 160,921 | 06 Jan 2026 | Direct |
| Maximo F. Nougues | PBYI | Common Stock | Sale | -2.22% | $26,532 | $5.84 | -4,540 | 199,689 | 06 Jan 2026 | Direct |
| Michael Patrick Miller | PBYI | Common Stock | Sale | -27% | $97,228 | $4.86 | -20,000 | 54,000 | 11 Nov 2025 | Direct |
* marks a reported price that did not pass the local price check.